Most Recent
Energy Beverages wins fight over Kangaroo Mother trade mark
Appeals 2023-08-24 11:54 pm By Christine Caulfield

The maker of Mother energy drinks has won an appeal of an IP Australia decision, succeeding in its bid to prevent a Victoria-based company from registering Kangaroo Mother as a trade mark for beverages.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Novartis can’t have separate trial on blood pressure drug invalidity claim
Ashurst 2023-08-18 10:04 pm By Cindy Cameronne

Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent. 

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Federal Court rejects ToolGen’s genome editing patent
Ashurst 2023-07-20 9:49 pm By Cindy Cameronne

A judge has upheld findings from IP Australia that South Korean biotech ToolGen’s genome editing technology CRISPR is not patentable, but given the company one more chance to seek to amend its application.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Cotton On lashes out at infringement claims, says copying rife in fashion industry
By George Legal 2021-12-21 4:08 pm By Bianca Hrovat

Retail giant Cotton On has hit back at allegations of copyright infringement, highlighting the prevalence of copying in the fashion industry.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Full Court upholds Sequenom’s win in patent battle over prenatal genetic tests
Adrian Ryan 2021-06-21 6:34 pm By Miklos Bolza

The Full Federal Court has upheld US biotech company Sequenom’s  patent for a noninvasive prenatal genetic test, rejecting rival Ariosa Diagnostic’s argument that the patent merely described a way to extract incorporeal genetic information.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Janssen triumphs again in battle to protect HIV drug patents
Angela McDonald 2021-05-24 10:24 am By Cat Fredenburgh

Juno Pharmaceuticals has backed away from its plans to launch a generic version of HIV drug Prezista in Australia after being hit with a patent lawsuit by Janssen, becoming the second generic drug maker to capitulate to the Johnson & Johnson-owned company’s demands.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Mylan fails in High Court bid to save patents for top seller Lipidil
Appeals 2020-11-06 12:06 pm By Cat Fredenburgh

The High Court has declined to take up Mylan’s challenge to a Full Court ruling upholding the invalidity of three patents for its blockbuster cholesterol drug Lipidil.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Designer hit with indemnity costs for bikini trade mark suit that ‘cried out to be settled’
Actuate Legal 2020-09-28 4:21 pm By Christine Caulfield

Women’s fashion designer Pinnacle Runway must pay indemnity costs for pursuing what a judge has described as an “ill-advised” trade mark infringement lawsuit against a rival that “cried out to be settled”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Tile maker Ceramiche wins trade mark fight with Caesarstone after ‘honest use’ ruling
Appeals 2020-07-29 3:28 pm By Christine Caulfield

Tile maker Ceramiche Caesar has prevailed in its challenge to a judge’s ruling allowing building products manufacturer Caesarstone to register two trade marks despite a finding that they were deceptively similar to one of its marks.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Mylan loses Lipidil appeal, despite court finding proof of intention not needed for Swiss-style claims
Appeals 2020-07-03 5:27 pm By Miklos Bolza

Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?